Last updated: 04/28/2020 22:20:05
A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation.
Trial description: A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, et. al. A Controlled Trial of Sustained-Release Bupropion, A Nicotine Patch, or Both for Smoking Cessation. N Engl J Med 1999; 340:685-91.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-16-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website